CPIX
Cumberland Pharmaceuticals Inc
7.10$
-4.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 17.5% | 16.4% | 18.5% | 17.4% | 14.6% | 18.9% | 12.2% | 18.6% | 11.9% | 16.4% | 21.2% | 22.5% | 16.6% | |
| 82.5% | 83.6% | 81.5% | 82.6% | 85.4% | 81.1% | 87.8% | 81.4% | 88.1% | 83.6% | 78.8% | 77.5% | 83.4% | |
| 19.1% | 13.5% | 13.6% | 10.8% | 14.4% | 12.4% | 11.1% | 13.5% | 15.1% | 11.3% | 16.0% | 463.9% | 16.1% | |
| 23.2% | 36.8% | 27.9% | 28.0% | 29.4% | 31.9% | 21.0% | 26.5% | 31.0% | 29.5% | 28.0% | 1,530.5% | 37.5% | |
| 101.0% | 149.7% | 103.5% | 93.1% | 104.1% | 98.7% | 76.8% | 88.3% | 111.8% | 93.6% | 113.1% | 1,976.2% | 114.2% | |
| -18.5% | -66.1% | -22.0% | -10.4% | -18.6% | -17.7% | 11.0% | -6.9% | -23.7% | -10.0% | -34.3% | -1,898.7% | -30.8% | |
| 1.1% | 1.9% | 1.4% | 1.3% | 1.5% | 2.1% | 1.4% | 1.0% | 1.3% | 0.8% | 0.9% | 0.4% | 1.0% | |
| -10.5% | -67.1% | -22.3% | -11.1% | -16.8% | -18.8% | 10.7% | -6.7% | -23.4% | -10.3% | -34.4% | -1,862.5% | -30.7% | |
| 0.1% | 0.3% | 0.1% | 0.1% | 0.1% | -0.5% | 0.0% | 0.1% | 0.1% | 0.2% | 0.0% | 2.3% | 0.1% | |
| -10.4% | -67.3% | -22.9% | -11.0% | -17.0% | -18.2% | 10.7% | -6.8% | -23.4% | -10.3% | -34.4% | -2,472.5% | -33.9% | |
| 5.4% | -43.1% | -4.0% | 4.7% | 0.1% | 0.4% | 23.3% | 6.5% | -9.6% | 0.3% | -19.4% | -1,876.2% | -18.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.